Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Neion Bio, fresh from stealth mode, signed its first co‑development and supply agreement with a major global pharmaceutical company to produce recombinant biologics using its egg‑based Raptor™ platform. The deal provides upfront and milestone payments plus profit‑sharing after commercialization, delivering near‑term revenue. Neion claims the platform can cut biomanufacturing costs by an order of magnitude and accelerate protein production. Founded in 2024 with $11 million in seed financing, the company aims to disrupt traditional cell‑culture processes.
@Ronalfa is speaking at @SynBioBeta in May and you probably already know who he is if you've been paying any attention to the AI x bio space. Ron spent years at @RecursionPharma as SVP of Research and acting CSO, helping build...
In this episode of Touching Base, the Gen editorial team discusses the latest advances in AI for life sciences, including NVIDIA’s GTC announcements on agentic AI, the deployment of 3,500 GPUs by Roche, and the emergence of open‑source autonomous agents...
Researchers at Denmark's DTU unveiled PathogenFinder2, an AI system that screens unknown bacteria for disease‑linked genes using protein language models. Trained on over 21,000 genomes, the tool predicts pathogenic potential even for species with no known relatives and highlights the...
A study by Anhui Medical University and Fudan University shows that polylactic acid (PLA), a widely used biodegradable bioplastic, breaks down into oligomeric lactic acid (OLA) nanoplastics that cross the placental barrier in mice. Exposure to environmentally relevant OLA doses...
A 12‑week high‑intensity interval training (HIIT) program was administered to 236 non‑athletic Han Chinese university students and genotyped for APOE variants. The promoter SNP rs405509 emerged as the sole polymorphism linked to body‑composition outcomes, with the GG genotype showing higher...
The Trump administration failed to meet the 210‑day deadline to nominate a permanent CDC director, leaving the agency without confirmed leadership for most of the second term. Meanwhile, the FDA granted accelerated approval to Denali Therapeutics’ Avlayah, the first enzyme...
Researchers at Cold Spring Harbor Laboratory published a Nature paper showing that antibodies generated against NMDA‑receptor‑expressing tumors can both boost anti‑cancer immunity and trigger autoimmune encephalitis. In mouse models, strong anti‑NMDA antibody responses correlated with robust tumor control, yet the...
Pinnacle Medicines announced the closing of an oversubscribed $89 million Series B financing, co‑led by LAV and Foresite Capital. The biotech firm leverages a proprietary platform that blends physics‑based molecular simulations, AI‑driven design, and advanced peptide chemistry to create oral peptide therapeutics....
Most cancer drugs go after the same targets: EGFR. PD-L1. HER2. Not because they’re the best targets. Because they’re the only ones we’ve been able to see. RyboDyn Inc. is going after what’s been invisible. The San Diego team, led by Imad Ajjawi, PhD,...
The ESPRESSO trial tested whether adding 90 minutes of high‑intensity hand and arm therapy each day for the first two weeks after stroke improves recovery. Sixty‑four participants received either immersive video‑game‑based or conventional therapy alongside standard care, but three‑month outcomes...
The FDA’s upcoming user‑fee framework, dubbed "America First," seeks to tighten eligibility for the small‑business waiver, limiting it to U.S.‑based applicants. Industry groups argue the change politicizes fee policy and could disadvantage foreign‑owned biotech firms that rely on the waiver...
Researchers applied a genome‑wide variance decomposition across TCGA’s 60,656 genes and 33 cancer types to prioritize therapeutic antigens, moving beyond traditional mean‑expression screens. The analysis yielded 17 candidates that met functional dependency, safety, and immune‑cold criteria, with three highlighted: CRIPTO/TDGF1,...
Researchers applied network pharmacology, molecular docking, and molecular dynamics to assess bioactive compounds from Pleurotus membranaceus for lung adenocarcinoma therapy. Four compounds passed drug‑likeness filters, linking to 226 overlapping disease targets and highlighting five hub genes. Docking showed isosorbide binding...
A cross‑sectional study of 33 early‑treated PKU children found ocular abnormalities common, linked to higher serum phenylalanine. Comprehensive eye exams revealed anterior and posterior segment issues. ROC analysis defined phenylalanine thresholds that predict elevated ocular risk. Findings suggest metabolic control...
Valneva SE announced its participation in the 26th World Vaccine Congress in Washington, D.C., from March 31 to April 2, 2026. The company’s CEO, Thomas Lingelbach, and senior executives will present data on the chikungunya vaccine IXCHIQ® and join a...
Transgene (Euronext: TNG) will deliver a 30‑minute oral presentation on its individualized neoantigen therapeutic vaccine TG4050 at the World Vaccine Congress in Washington, D.C. on April 1, 2026. TG4050, built on the AI‑driven myvac® platform, targets patient‑specific tumor mutations. Phase 1 data in...
The GLP‑1 drug semaglutide has entered the Indian market as generic versions after its patent expired last week, driving monthly prices down from roughly $144 to $36. The steep discount makes the medication affordable for a broader segment of diabetics...
The University of Rochester Medical Center’s Center for Community Health & Prevention is urging patients on GLP‑1 weight‑loss medications to enroll in nutrition counseling. The guidance highlights 80‑100 g of daily protein and adequate hydration to protect muscle mass and curb...
Researchers led by Dr Krish Sanghvi at Oxford analyzed 115 studies of 55,000 men and found that longer abstinence increases sperm DNA damage. Men who ejaculated less than 48 hours before IVF achieved a 46% pregnancy rate versus 36% for the standard...
Cellular senescence has become a focal point for longevity medicine, prompting a surge of senolytic and senomorphic drug development. Pioneering studies showed that clearing senescent cells can extend healthspan, leading biotech firms like Rubedo, SENISCA, Deciduous Therapeutics, and Arda Therapeutics...
A research team has created magnetic silk‑iron nanoparticles that can be steered with external magnetic fields to deliver therapeutics to otherwise inaccessible disease locations. The nanoplatform merges biocompatible silk fibroin with iron oxide, enabling magnetic control while maintaining safety, a...
The World Health Organization announced new policy guidance aimed at simplifying tuberculosis detection tests, signaling a major push for more accessible diagnostics. While the guidance outlines a framework for low‑cost, point‑of‑care testing, specific technical details were not disclosed in the...
One large psilocybin dose beat nicotine patches by 6x odds for smoking cessation. 82 otherwise-healthy cigarette smokers, 42 received a single high-dose 30mg/70kg psilocybin session, and 40 initiated an 8- to 10-week course of nicotine patch treatment. At 6 months; participants were 6x...
Jona, an AI‑driven gut microbiome startup, has teamed up with Everlywell to bring a high‑resolution microbiome test to the U.S. consumer market. The test employs deep shotgun metagenomic sequencing, delivering strain‑level data on bacteria, fungi, viruses and parasites. Jona’s proprietary...
Kodiak Sciences announced that its experimental eye drug Zenkuda (tarcocimab tedromer) achieved positive topline results in the GLow2 Phase 3 trial for diabetic retinopathy, outperforming sham treatment. The study met its primary endpoint, delivering a statistically significant gain in visual acuity...
Researchers at Israel's Volcani Center used CRISPR/Cas9 to inactivate the 1,2RhaT gene in Citrus paradisi, effectively halting production of bitter compounds such as naringin, neohesperidin, and poncirin in leaf tissue. The gene edit eliminates the bitter taste pathway, and the...
Cryopreservation remains a linchpin for cell and gene therapy (CGT) manufacturing, yet frozen material is not inherently stable. Real‑world operations introduce transient warming events (TWEs) when products are moved, accessed, or shipped, silently degrading viability and potency. Traditional reliance on...
Dr. Emanuela Offidani, Tris Pharma’s Medical Director of Digital Health Strategy, highlighted that ADHD is increasingly recognized as a lifelong condition that often goes undiagnosed in women because symptoms are less overt. She explained that Tris Pharma’s proprietary LiquiXR delivery...
I have a story today about the quest to turn eggs into low-cost factories for medicines. Gift link: https://nyti.ms/4bzSabB
The Pistoia Alliance has published a peer‑reviewed best‑practice framework guiding ethical use of social‑media listening in drug development. The framework, co‑authored by experts from Bayer, Roche, Boehringer Ingelheim, Chiesi and Semalytix, outlines standards for data anonymization, bias mitigation, and AI‑driven...
Corcept Therapeutics saw its shares climb almost 20% after the U.S. FDA approved its lead drug Lifyorli in combination with nab‑paclitaxel for platinum‑resistant ovarian, fallopian tube and primary peritoneal cancer. The approval, based on a 381‑patient trial, validates the company's...
Precigen (PGEN) reported fiscal Q4 2025 revenue of $9.7 million, up 149% year‑over‑year, and projected first‑quarter 2026 sales to exceed $18 million. The surge stems from the rapid commercial rollout of its FDA‑approved gene‑therapy Papzimius and broader payer coverage across the United...
Biotech start‑up Neion Bio is pioneering a method to turn chicken embryos into miniature drug factories. Scientists micro‑inject genetic constructs into three‑day‑old embryos, reprogramming the developing bird to synthesize pharmaceutical compounds within the egg. The approach promises faster, cheaper production...
Novocure disclosed topline Phase‑2 PANOVA‑4 data showing that Tumor‑Treating Fields (TTFields) combined with Tecentriq and gemcitabine/nab‑paclitaxel achieved a 74.4% disease‑control rate in metastatic pancreatic ductal adenocarcinoma (mPDAC). The trial, enrolling 78 patients, outperformed the historical MPACT control arm’s 48% DCR. Secondary...
“These findings challenge the assumption that lifespan extension necessarily compresses morbidity, highlighting the need to consider lifespan, healthspan, and CoM as endpoints when evaluating anti-aging interventions. We do not claim that life-extending interventions categorically fail to achieve CoM; rather, we demonstrate...
A “kazarian?” Is that like a Kardashian? What planet are these X trolls from? I develop low-cost often patent-free vaccines for global health and to help humanity. So far 100 million have benefited from access to our vaccine technologies developed...
A Nestlé‑backed randomized trial gave healthy men 714 mg nicotinamide and 19 mg pyridoxine daily for nine days after intense eccentric exercise. The B‑vitamin combo boosted muscle stem cell numbers by 29% and accelerated differentiation markers—MyoD+ cells rose 67%, myogenin+ cells 34%,...
🆕 @ScienceMagazine How do our cells have long term memory of inflammation that can later lead to persistent, chronic inflammation and disease? Through specific epigenetic chromatin changes, aka "memory domains" @ScienceVisuals https://t.co/mt70OwH144 https://t.co/DMk7SaIuBc https://t.co/FaPpN0331q
My article in today's issue of the Journal of the American Medical Association Health Forum, on FDA's new rare disease guidance, and how the agency can build on these policy steps to promote innovation for inherited disorders, authored with Maarika...
FDA clears Denali drug in ‘clear step’ for rare disease biotechs https://t.co/x9yL4nyPaj by Kristin Jensen $DNLI #biotech
Of all the IO companies I've met and covered in the past ~15 years I'm struggling to think of one that's been more disappointing vs its initial promise than $IPHYF. Will it even last beyond Q3? Via @ByMadeleineA -> https://t.co/DepdZfDBdY
This week's Biotech Scorecard: Allogene $ALLO: A preview of its April interim analysis. Very interesting (to me, at least) There just might be a path forward for off-the-shelf CAR-T therapy in B-cell lymphoma. Frontline consolidation. Read all about it: https://t.co/tcPFelUH3C
Gene therapy isn't just targeting diseases anymore—it's targeting aging itself. The hallmarks of aging are becoming editable code. Longevity Escape Velocity isn't a fantasy. It's an engineering problem. And we're solving it.
Harvard’s twistable light chip could give drug developers a new tool for sorting mirror-image molecules https://t.co/WkjjD38exo https://t.co/5kr4d9f6sa
I almost sent a figure with wrong cluster labels to my collaborators. The R code ran perfectly. No errors, no warnings. I caught it because cluster 2 showed upregulated genes in RNAseq but reduced chromatin accessibility in ATACseq. Biologically, that's backwards....
Pretty sweet setup for BiotechTv interviews at @MassBio State of Possible Conference today. If you are here, please stop by and say hello.👋 https://t.co/CQtXLi36Qk
